Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Not Currently Receiving Inhaled Corticosteroids
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
California
-
Long Beach, California, Estados Unidos, 90808
- GSK Investigational Site
-
Los Angeles, California, Estados Unidos, 90025
- GSK Investigational Site
-
Newport Beach, California, Estados Unidos, 92663
- GSK Investigational Site
-
-
Georgia
-
Albany, Georgia, Estados Unidos, 31707
- GSK Investigational Site
-
-
Missouri
-
Columbia, Missouri, Estados Unidos, 65203
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73103
- GSK Investigational Site
-
-
South Carolina
-
Orangeburg, South Carolina, Estados Unidos, 29118
- GSK Investigational Site
-
Spartanburg, South Carolina, Estados Unidos, 29303
- GSK Investigational Site
-
-
Texas
-
Corsicana, Texas, Estados Unidos, 75110
- GSK Investigational Site
-
Waco, Texas, Estados Unidos, 76712
- GSK Investigational Site
-
-
-
-
-
Klin, Federação Russa, 141600
- GSK Investigational Site
-
Moscow, Federação Russa, 115446
- GSK Investigational Site
-
Saratov, Federação Russa, 410028
- GSK Investigational Site
-
St. Petersburg, Federação Russa, 194356
- GSK Investigational Site
-
Voronezh, Federação Russa, 394066
- GSK Investigational Site
-
Yaroslavl, Federação Russa, 150003
- GSK Investigational Site
-
-
-
-
Jalisco
-
Zapopan, Jalisco, México, 45040
- GSK Investigational Site
-
-
Michoacán
-
Morelia, Michoacán, México, 58070
- GSK Investigational Site
-
-
Tabasco
-
Villahermosa, Tabasco, México, 86100
- GSK Investigational Site
-
-
-
-
-
Lima, Peru, Lima 1
- GSK Investigational Site
-
Lima, Peru, Lima 27
- GSK Investigational Site
-
-
Lima
-
Lima 18, Lima, Peru
- GSK Investigational Site
-
San Borja, Lima, Peru, Lima 41
- GSK Investigational Site
-
San Miguel, Lima, Peru, Lima 32
- GSK Investigational Site
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Signed informed consent
- Outpatient at least 12 years of age with diagnosis of asthma at least 12 weeks before first visit
- Both genders; females of child bearing potential must be willing to use appropriate contraception during the study
- Pre-bronchodilator FEV1 of at least 60% predicted
- FEV1 reversibility of at least 12% and 200mls
- Current asthma therapy that includes a non-corticosteroid controller and/or short-acting beta agonist
Exclusion Criteria:
- History of life-threatening asthma exacerbation within the past 10 years
- Asthma exacerbation requiring treatment with oral corticosteroids within the last 3 months or that required overnight hospital stay within 6 months
- Current or recent respiratory infection or current oral candida infection
- Presence of another significant respiratory disease or medical condition that is not controlled or that could affect subject safety or study outcome
- Known or suspected allergy to study drug or materials
- Taking another investigational medication or prohibited medication during the study
- Previous treatment with inhaled fluticasone furoate in a phase II or III study
- Current smokers or former smokers with significant tobacco exposure
- Children in Care
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Fluticasone furoate 50mcg
Inhalation powder delivered by Novel Dry Powder Inhaler
|
Inhalation powder delivered by Novel Dry Powder Inhaler
|
|
Comparador de Placebo: Placebo
Inhalation powder delivered by Novel Dry Powder Inhaler
|
Inhalation powder delivered by Novel Dry Powder Inhaler
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Clinic Visit Evening (Pre-bronchodilator and Pre-dose) Forced Expiratory Volume in One Second (FEV1) at the End of the 12-week Treatment Period
Prazo: Baseline and Week 12
|
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second.
Evening clinic visit FEV1 is defined as the clinic visit (pre-bronchodilator and pre-dose) FEV1 measurement taken at the Week 12 clinic visit.
Pre-dose and pre-rescue albuterol/salbutamol trough FEV1 were measured electronically by spirometry in the evening at the Baseline through Week 12 clinic visits.
The highest of 3 technically acceptable measurements was recorded.
Baseline was the pre-dose value obtained at Visit 2. Change from Baseline was calculated as the Week 12 value minus the Baseline value.
Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline, region, sex, age, and treatment.
The last observation carried forward (LOCF) method was used to impute missing data, in which the last non-missing, pre-dose, post-Baseline on-treatment measurement at scheduled clinic visits was used to impute the missing value.
|
Baseline and Week 12
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods Over the 12-week Treatment Period
Prazo: From Baseline up to Week 12
|
The number of inhalations of rescue bronchodilator, albuterol/salbutamol inhalation aerosol, used during the day and night was recorded by the participants in a daily electronic diary (eDiary).
A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no use of rescue medication was considered to be rescue free.
A 24-hour period was considered as missing if both day time and night time values were missing or if one of the day time or night time values were missing and the other value indicated no use of rescue medication.
The Baseline value is the average of the values over the last 7 days of the daily eDiary prior to the randomization of the participant.
Change from Baseline was calculated as the averaged value during the 24-week Treatment Period minus the Baseline value.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
From Baseline up to Week 12
|
|
Change From Baseline in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Prazo: From Baseline up to Week 12
|
PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated.
PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use.
Change from Baseline (defined as the average of the values of the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily trough PM PEF over the 12-week Treatment Period minus the Baseline value.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
From Baseline up to Week 12
|
|
Change From Baseline in Daily Morning (AM) PEF Averaged Over the 12-week Treatment Period
Prazo: From Baseline up to Week 12
|
PEF is a measure of lung function and is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated.
PEF was measured by the participants using a hand-held electronic peak flow meter each morning and evening prior to the dose of study medication and any rescue albuterol/salbutamol inhalation aerosol use.
Change from Baseline (defined as the average of the values of the last 7 days prior to randomization of the participants) was calculated as the value of the averaged daily AM PEF over the 12-week Treatment Period minus the Baseline value.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
From Baseline up to Week 12
|
|
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods Over the 12-week Treatment Period
Prazo: From Baseline up to Week 12
|
Asthma symptoms were recorded in a daily eDairy by the participants every day in the morning and evening before taking any rescue or study medication and before the peak expiratory flow measurement.
A 24-hour period in which a participant's responses to both the morning and evening assessments indicated no symptoms was considered to be symptom free.
A 24-hour period was considered as missing if both the day time and night time data were missing or if one was symptom-free but the other was missing.
The Baseline value was the average of the values of the last 7 days of the daily eDiary prior to the randomization of the participant.
Change from Baseline was calculated as the averaged value during the 12-week Treatment Period minus the Baseline value.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
From Baseline up to Week 12
|
|
Number of Participants Who Withdrew Due to a Lack of Efficacy During the 12-week Treatment Period
Prazo: From the first dose of the study medication until Week 12/Early Withdrawal
|
The reason for withdrawal was lack of efficacy if a participant was withdrawn due to: clinic FEV1 falling below the FEV1 stability limit; participant experiencing at least 4 days of AM or PM PEF falling below the PEF stability limit and/or at least 3 days of >=12 inhalations/day of albuterol/salbutamol usage during the 7 days immediately preceding any contact; or the occurrence of an asthma exacerbation, defined as the deterioration of asthma requiring the use of systemic (oral, parenteral, or depot) corticosteroids for at least 3 days or an in-patient hospitalization or emergency department visit due to asthma that required systemic corticosteroids.
The FEV1 stability limit was calculated as the best pre-salbutamol/albuterol FEV1 at Visit 2 * 80%.
The PEF stability limit was calculated as the mean AM PEF from the available 7 consecutive days preceding Visit 2 * 80%.
|
From the first dose of the study medication until Week 12/Early Withdrawal
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Publicações e links úteis
Publicações Gerais
- O'Byrne PM, Jacques L, Goldfrad C, Kwon N, Perrio M, Yates LJ, Busse WW. Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. Respir Res. 2016 Nov 24;17(1):157. doi: 10.1186/s12931-016-0473-x.
- O'Byrne PM, Woodcock A, Bleecker ER, Bateman ED, Lotvall J, Forth R, Medley H, Jacques L, Busse WW. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respir Res. 2014 Aug 11;15(1):88. doi: 10.1186/s12931-014-0088-z.
- Svedsater H, Jacques L, Goldfrad C, Bleecker ER. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014 Jun 26;24:14019. doi: 10.1038/npjpcrm.2014.19. No abstract available.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Respiratórias
- Doenças do sistema imunológico
- Doenças pulmonares
- Hipersensibilidade, Imediata
- Doenças brônquicas
- Doenças Pulmonares Obstrutivas
- Hipersensibilidade Respiratória
- Hipersensibilidade
- Asma
- Efeitos Fisiológicos das Drogas
- Agentes Autônomos
- Agentes do Sistema Nervoso Periférico
- Antiinflamatórios
- Agentes dermatológicos
- Agentes broncodilatadores
- Agentes Antiasmáticos
- Agentes do Sistema Respiratório
- Agentes Antialérgicos
- Fluticasona
- Xhance
Outros números de identificação do estudo
Outros números de identificação do estudo
- 115283
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Dados/documentos do estudo
-
Plano de Análise Estatística
Identificador de informação: 115283Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Especificação do conjunto de dados
Identificador de informação: 115283Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocolo de estudo
Identificador de informação: 115283Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Relatório de Estudo Clínico
Identificador de informação: 115283Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Consentimento Informado
Identificador de informação: 115283Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Conjunto de dados de participantes individuais
Identificador de informação: 115283Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulário de Relato de Caso Anotado
Identificador de informação: 115283Comentários informativos: For additional information about this study please refer to the GSK Clinical Study Register
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .